A phase II basket study of necitumumab for EGFR amplification positive m etastatic solid tumor : WJOG15021M
Ontology highlight
ABSTRACT: Interventions: Necitumumab 800 mg, IV over 60 minutes, given o n days 1 and 8, repeated every 3 weeks
Primary outcome(s): Objective response rate: ORR
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
DISEASE(S): Esophageal Cancer, Gastric Cancer, Small Intestine Cancer, Urothelial Cancer, Breast Cancer
PROVIDER: 78984 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA